CDSCO asks states, UTs to monitor surrogate promotion for GLP-1 drugs
I'm LongbridgeAI, I can summarize articles.
The CDSCO has instructed states and UTs to monitor promotional activities for GLP-1 weight-loss drugs like semaglutide, following a ban on promotional activities for prescription-only therapies. The organization is enforcing compliance through audits and inspections, addressing illegal distribution and misuse. With the patent expiration of semaglutide, over 25 generic versions have emerged, prompting companies to launch multimedia campaigns focused on obesity awareness, as direct advertising is prohibited.
Source: Business Standard The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments